CN102099021A - Hdac抑制剂用于治疗霍奇金病的应用 - Google Patents

Hdac抑制剂用于治疗霍奇金病的应用 Download PDF

Info

Publication number
CN102099021A
CN102099021A CN2009801279739A CN200980127973A CN102099021A CN 102099021 A CN102099021 A CN 102099021A CN 2009801279739 A CN2009801279739 A CN 2009801279739A CN 200980127973 A CN200980127973 A CN 200980127973A CN 102099021 A CN102099021 A CN 102099021A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
polycyclic
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801279739A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·阿塔贾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102099021A publication Critical patent/CN102099021A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801279739A 2008-07-18 2009-07-16 Hdac抑制剂用于治疗霍奇金病的应用 Pending CN102099021A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8180508P 2008-07-18 2008-07-18
US61/081,805 2008-07-18
PCT/US2009/050768 WO2010009280A1 (en) 2008-07-18 2009-07-16 Use of hdac inhibitors for the treatment of hodgkin's disease

Publications (1)

Publication Number Publication Date
CN102099021A true CN102099021A (zh) 2011-06-15

Family

ID=41128203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801279739A Pending CN102099021A (zh) 2008-07-18 2009-07-16 Hdac抑制剂用于治疗霍奇金病的应用

Country Status (15)

Country Link
US (1) US20110118309A1 (https=)
EP (1) EP2306996A1 (https=)
JP (1) JP2011528662A (https=)
KR (1) KR20110031980A (https=)
CN (1) CN102099021A (https=)
AU (1) AU2009270886A1 (https=)
BR (1) BRPI0915927A2 (https=)
CA (1) CA2730738A1 (https=)
CL (1) CL2011000100A1 (https=)
IL (1) IL210489A0 (https=)
MA (1) MA32482B1 (https=)
MX (1) MX2011000719A (https=)
TW (1) TW201006470A (https=)
WO (1) WO2010009280A1 (https=)
ZA (1) ZA201100165B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796514A (zh) * 2011-07-07 2014-05-14 美国癌症研究所 用于治疗癌症的系统、方法和制剂
CN109705057A (zh) * 2017-10-25 2019-05-03 成都先导药物开发有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11369585B2 (en) 2017-03-17 2022-06-28 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP4054574A4 (en) * 2019-11-06 2023-12-06 Dana-Farber Cancer Institute, Inc. SELECTIVE HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADING AGENTS AND METHODS OF USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
RU2009102275A (ru) * 2006-06-26 2010-08-10 Новартис АГ (CH) Органические соединения
MY148893A (en) * 2006-12-04 2013-06-14 Novartis Ag Combination of an hdac inhibitor and an antimetabolite

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796514A (zh) * 2011-07-07 2014-05-14 美国癌症研究所 用于治疗癌症的系统、方法和制剂
CN109675041A (zh) * 2011-07-07 2019-04-26 美国癌症研究所 用于治疗癌症的系统、方法和制剂
CN109705057A (zh) * 2017-10-25 2019-05-03 成都先导药物开发有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途

Also Published As

Publication number Publication date
WO2010009280A1 (en) 2010-01-21
MA32482B1 (fr) 2011-07-03
TW201006470A (en) 2010-02-16
ZA201100165B (en) 2011-09-28
CA2730738A1 (en) 2010-01-21
KR20110031980A (ko) 2011-03-29
MX2011000719A (es) 2011-03-01
EP2306996A1 (en) 2011-04-13
CL2011000100A1 (es) 2011-07-01
JP2011528662A (ja) 2011-11-24
AU2009270886A1 (en) 2010-01-21
BRPI0915927A2 (pt) 2016-06-07
US20110118309A1 (en) 2011-05-19
IL210489A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
KR101561750B1 (ko) Ｍｄｍ2/4 및 ｐ53 상호작용의 억제제의 결정질 형태
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
CN102099021A (zh) Hdac抑制剂用于治疗霍奇金病的应用
TW201605450A (zh) Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN102065859B (zh) 用于神经纤维瘤病的取代的苯并咪唑类
JP6526789B2 (ja) 組み合わせ療法
WO2010009285A1 (en) Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
JP2012516345A (ja) 星細胞腫治療用置換ベンゾイミダゾール
HK40064964A (en) Combination products with tyrosine kinase inhibitors and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110615